Cytotoxic therapy and other nonhormonal approaches for the treatment of metastatic breast cancer

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

I. INTRODUCTION Metastatic breast cancer is an incurable disease that is typically associated with a median survival of approximately 18 to 24 months. The goals of systemic therapy include palliation of symptoms, prolongation of survival, and in rare cases prolongation of disease-free survival beyond 5 years. Current options for systemic therapy include hormonal therapy for those with estrogen and/or progesterone receptor-positive disease, trastuzumab for those with disease that overexpresses Her2/neu, and cytotoxic chemotherapy. Cytotoxic therapy is generally reserved for patients with hormone-sensitive disease who have failed one or more hormonal regimens or those with who have symptomatic disease that requires prompt symptom relief. This chapter focuses on the efficacy of cytotoxic therapy and other nonhormonal approaches for the treatment of patients with metastatic breast cancer. The emphasis is on clinical trials that have been reported within the past decade-either randomized Phase III trials or selected Phase II trials that have had a substantial impact on the field. Endpoints reviewed for selected studies include response rate, median time to disease progression (or treatment failure), median survival, and the incidence of severe (grade 3) and life-threatening (grade 4) toxicities.

Original languageEnglish (US)
Title of host publicationBreast Cancer
Subtitle of host publicationPrognosis, Treatment, and Prevention
PublisherCRC Press
Pages417-472
Number of pages56
ISBN (Electronic)9780203909249
ISBN (Print)9780824707125
StatePublished - Jan 1 2002

Fingerprint

Breast Neoplasms
Survival
Therapeutics
Progesterone Receptors
Treatment Failure
Estrogen Receptors
Disease-Free Survival
Disease Progression
Clinical Trials
Hormones
Drug Therapy
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sparano, J. A. (2002). Cytotoxic therapy and other nonhormonal approaches for the treatment of metastatic breast cancer. In Breast Cancer: Prognosis, Treatment, and Prevention (pp. 417-472). CRC Press.

Cytotoxic therapy and other nonhormonal approaches for the treatment of metastatic breast cancer. / Sparano, Joseph A.

Breast Cancer: Prognosis, Treatment, and Prevention. CRC Press, 2002. p. 417-472.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sparano, JA 2002, Cytotoxic therapy and other nonhormonal approaches for the treatment of metastatic breast cancer. in Breast Cancer: Prognosis, Treatment, and Prevention. CRC Press, pp. 417-472.
Sparano JA. Cytotoxic therapy and other nonhormonal approaches for the treatment of metastatic breast cancer. In Breast Cancer: Prognosis, Treatment, and Prevention. CRC Press. 2002. p. 417-472
Sparano, Joseph A. / Cytotoxic therapy and other nonhormonal approaches for the treatment of metastatic breast cancer. Breast Cancer: Prognosis, Treatment, and Prevention. CRC Press, 2002. pp. 417-472
@inbook{2dc715d8b8944e819774a26ccc7fbb92,
title = "Cytotoxic therapy and other nonhormonal approaches for the treatment of metastatic breast cancer",
abstract = "I. INTRODUCTION Metastatic breast cancer is an incurable disease that is typically associated with a median survival of approximately 18 to 24 months. The goals of systemic therapy include palliation of symptoms, prolongation of survival, and in rare cases prolongation of disease-free survival beyond 5 years. Current options for systemic therapy include hormonal therapy for those with estrogen and/or progesterone receptor-positive disease, trastuzumab for those with disease that overexpresses Her2/neu, and cytotoxic chemotherapy. Cytotoxic therapy is generally reserved for patients with hormone-sensitive disease who have failed one or more hormonal regimens or those with who have symptomatic disease that requires prompt symptom relief. This chapter focuses on the efficacy of cytotoxic therapy and other nonhormonal approaches for the treatment of patients with metastatic breast cancer. The emphasis is on clinical trials that have been reported within the past decade-either randomized Phase III trials or selected Phase II trials that have had a substantial impact on the field. Endpoints reviewed for selected studies include response rate, median time to disease progression (or treatment failure), median survival, and the incidence of severe (grade 3) and life-threatening (grade 4) toxicities.",
author = "Sparano, {Joseph A.}",
year = "2002",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780824707125",
pages = "417--472",
booktitle = "Breast Cancer",
publisher = "CRC Press",

}

TY - CHAP

T1 - Cytotoxic therapy and other nonhormonal approaches for the treatment of metastatic breast cancer

AU - Sparano, Joseph A.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - I. INTRODUCTION Metastatic breast cancer is an incurable disease that is typically associated with a median survival of approximately 18 to 24 months. The goals of systemic therapy include palliation of symptoms, prolongation of survival, and in rare cases prolongation of disease-free survival beyond 5 years. Current options for systemic therapy include hormonal therapy for those with estrogen and/or progesterone receptor-positive disease, trastuzumab for those with disease that overexpresses Her2/neu, and cytotoxic chemotherapy. Cytotoxic therapy is generally reserved for patients with hormone-sensitive disease who have failed one or more hormonal regimens or those with who have symptomatic disease that requires prompt symptom relief. This chapter focuses on the efficacy of cytotoxic therapy and other nonhormonal approaches for the treatment of patients with metastatic breast cancer. The emphasis is on clinical trials that have been reported within the past decade-either randomized Phase III trials or selected Phase II trials that have had a substantial impact on the field. Endpoints reviewed for selected studies include response rate, median time to disease progression (or treatment failure), median survival, and the incidence of severe (grade 3) and life-threatening (grade 4) toxicities.

AB - I. INTRODUCTION Metastatic breast cancer is an incurable disease that is typically associated with a median survival of approximately 18 to 24 months. The goals of systemic therapy include palliation of symptoms, prolongation of survival, and in rare cases prolongation of disease-free survival beyond 5 years. Current options for systemic therapy include hormonal therapy for those with estrogen and/or progesterone receptor-positive disease, trastuzumab for those with disease that overexpresses Her2/neu, and cytotoxic chemotherapy. Cytotoxic therapy is generally reserved for patients with hormone-sensitive disease who have failed one or more hormonal regimens or those with who have symptomatic disease that requires prompt symptom relief. This chapter focuses on the efficacy of cytotoxic therapy and other nonhormonal approaches for the treatment of patients with metastatic breast cancer. The emphasis is on clinical trials that have been reported within the past decade-either randomized Phase III trials or selected Phase II trials that have had a substantial impact on the field. Endpoints reviewed for selected studies include response rate, median time to disease progression (or treatment failure), median survival, and the incidence of severe (grade 3) and life-threatening (grade 4) toxicities.

UR - http://www.scopus.com/inward/record.url?scp=84930795064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930795064&partnerID=8YFLogxK

M3 - Chapter

SN - 9780824707125

SP - 417

EP - 472

BT - Breast Cancer

PB - CRC Press

ER -